Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Rebimastat

Generic Name: Rebimastat

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₄₁N_₅O_₅S

CAS Number: 259188-38-0

Unique Ingredient Identifier: 1B47R6ZX4K

Overview

No overview information available.

Background

No background information available.

Indication

Investigated for use/treatment in lung cancer and prostate cancer.

Associated Conditions

No associated conditions information available.

Clinical Trials

BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma

Phase 1

Completed

Posted: 2003/08/05

Sponsor:National Cancer Inst...

ID:NCT00024024

Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer

Phase 2

Completed

Posted: 2003/07/25

Sponsor:NCIC Clinical Trials...

ID:NCT00006229

BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2

Completed

Posted: 2003/01/27

Sponsor:National Cancer Inst...

ID:NCT00040755

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

Phase 2

Completed

Posted: 2003/01/27

Sponsor:National Cancer Inst...

ID:NCT00039104

A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy

Phase 2

Terminated

Posted: 2002/05/13

Sponsor:Bristol-Myers Squibb

ID:NCT00036621

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy